Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination

Silva, Maria Luíza; Espírito-Santo, Luçandra Ramos; Martins, Maria Aparecida; Silveira-Lemos, Denise da; Peruhype-Magalhães, Vanessa; Caminha, Ricardo Carvalho; Maranhão-Filho, Péricles de Andrade; Auxiliadora‐Martins, Maria; Martins, Reinaldo de Menezes; Galler, Ricardo; Freire, Marcos da Silva; Marcovistz, Rugimar; Homma, Akira; Teuwen, Dirk E.; Elói-Santos, Silvana Maria; Andrade, Mariléia Cháves; Teixeira-Carvalho, Andréa; Martins‐Filho, Olindo Assis

doi:10.1128/cvi.00369-09

Cited by 47 publications

(36 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A depressed monocyte cytokine synthesis was found by our group in a case with a mixed pattern of viscerotropic and neurotropic disease, in a patient with SLE. 18 Strong responses in both cell-mediated and humoral responses were found in these cases and also in a fatal case in Spain. 19 As a rule, neutralizing antibody titers are high in YEL-AVD, and taken together these findings point to defects in innate response in YEL-AVD cases.…”

Section: Vaccine-associated Viscerotropicmentioning

confidence: 98%

Serious adverse events associated with yellow fever vaccine

Martins

Leal²,

Homma³

2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Section: Vaccine-associated Viscerotropicmentioning

confidence: 98%

Serious adverse events associated with yellow fever vaccine

Martins

Leal²,

Homma³

2015

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

“…First, ChinDENV utilizes the JE vaccine SA14-14-2, which has demonstrated an ideal safety profile in large-scale clinical usage, as the genetic backbone. Meanwhile, for YFV-17D, the backbone for CYD in clinical trials, vaccination-associated adverse events have been reported (83)(84)(85)(86)(87). Second, the Sanofi Pasteur's CYD2 vaccine carries the prM-E genes of Asian genotype I of DENV-2 (PUO-218 strain).…”

Section: Discussionmentioning

confidence: 99%

A Chimeric Dengue Virus Vaccine using Japanese Encephalitis Virus Vaccine Strain SA14-14-2 as Backbone Is Immunogenic and Protective against Either Parental Virus in Mice and Nonhuman Primates

Deng

Yang

et al. 2013

J Virol

View full text Add to dashboard Cite

The development of a safe and efficient dengue vaccine represents a global challenge in public health. Chimeric dengue viruses (DENV) based on an attenuated flavivirus have been well developed as vaccine candidates by using reverse genetics. In this study, based on the full-length infectious cDNA clone of the well-known Japanese encephalitis virus live vaccine strain SA14-14-2 as a backbone, a novel chimeric dengue virus (named ChinDENV) was rationally designed and constructed by replacement with the premembrane and envelope genes of dengue 2 virus. The recovered chimeric virus showed growth and plaque properties similar to those of the parental DENV in mammalian and mosquito cells. ChinDENV was highly attenuated in mice, and no viremia was induced in rhesus monkeys upon subcutaneous inoculation. ChinDENV retained its genetic stability and attenuation phenotype after serial 15 passages in cultured cells. A single immunization with various doses of ChinDENV elicited strong neutralizing antibodies in a dose-dependent manner. When vaccinated monkeys were challenged with wild-type DENV, all animals except one that received the lower dose were protected against the development of viremia. Furthermore, immunization with Chin-DENV conferred efficient cross protection against lethal JEV challenge in mice in association with robust cellular immunity induced by the replicating nonstructural proteins. Taken together, the results of this preclinical study well demonstrate the great potential of ChinDENV for further development as a dengue vaccine candidate, and this kind of chimeric flavivirus based on JE vaccine virus represents a powerful tool to deliver foreign antigens.

show abstract

“…The pathogenesis of YFV-AVD is similar to severe WT YFV infection with high case-fatality rates characterized by viral replication in numerous visceral tissues and liver histopathology (Belsher et al, 2007;Centers for Disease Control and Prevention, 2002;Cetron et al, 2002;Chan et al, 2001;Gerasimon & Lowry, 2005;Martin et al, 2001;Monath et al, 2013;Vasconcelos et al, 2001). Evaluation of the immune response in a few cases of YFV-17D-associated adverse events found elevated levels of liver enzymes and cytokines similar to WT YFV infection (Bae et al, 2008;Silva et al, 2010). It has been shown that YFV-17D can infect monocytes/macrophages and endothelial cells (Goodman & Koprowski, 1962;Khaiboullina et al, 2005;Liprandi & Walder, 1983;Meier et al, 2009;Schlesinger & Brandriss, 1981), and it has been proposed that these cells are a source of dysregulated cytokine secretion leading to sepsis (Khaiboullina et al, 2005;Monath & Barrett, 2003).…”

Section: Introductionmentioning

confidence: 99%